These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30272049)

  • 1. Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.
    Shancer Z; Williams M; Igelman A; Nagata S; Ise T; Pastan I; Bera TK
    Antib Ther; 2018 Jun; 1(1):19-25. PubMed ID: 30272049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
    Bera TK
    Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
    Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
    Wei J; Bera TK; Liu XF; Zhou Q; Onda M; Ho M; Tai CH; Pastan I
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3501-E3508. PubMed ID: 29581296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.
    Zheng Z; Okada R; Kobayashi H; Nagaya T; Wei J; Zhou Q; Lee F; Bera TK; Gao Y; Kuhlman W; Tai CH; Pastan I
    Mol Cancer Ther; 2020 Mar; 19(3):812-821. PubMed ID: 31871266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
    Reiter Y; Pastan I
    Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.
    Müller F; Cunningham T; Liu XF; Wayne AS; Pastan I
    Clin Cancer Res; 2016 Oct; 22(19):4913-4922. PubMed ID: 27114443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
    Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
    Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant immunotoxins with low endotoxins for clinical and animal studies.
    Onda M
    Methods Mol Biol; 2012; 907():627-43. PubMed ID: 22907377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxin-labeled monoclonal antibodies.
    Kreitman RJ
    Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 15. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
    Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
    Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.
    Zhu S; Liu Y; Wang PC; Gu X; Shan L
    Biomed Res Int; 2017; 2017():7929286. PubMed ID: 28752098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
    Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
    Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.